Related Experiment Video

Updated: Jul 14, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Ezetimibe plus fenofibrate: a new combination therapy for the management of mixed hyperlipidaemia?

Michel Farnier1

  • 1Point Médical, Rond Point de la Nation, 21000 Dijon, France. michelfarnier@nerim.net

Expert Opinion on Pharmacotherapy
|June 15, 2007
PubMed

Insights

Managing mixed hyperlipidaemia is challenging for cardiovascular disease prevention. Ezetimibe plus fenofibrate offers an alternative for patients not reaching lipid goals with statins alone.

Area of Science:

  • Cardiology
  • Pharmacology
  • Metabolic Disorders

Background:

  • Mixed hyperlipidaemia is a significant cardiovascular disease risk factor.
  • Achieving lipid target goals is often difficult with statin monotherapy.
  • Novel therapeutic strategies are needed for effective lipid management.

Purpose of the Study:

  • To evaluate the role of ezetimibe plus fenofibrate in managing mixed hyperlipidaemia.
  • To assess the combination therapy as an alternative to statin monotherapy.
  • To identify patient subgroups who may benefit most from this combination.

Main Methods:

  • Review of current clinical data on lipid-lowering therapies.
  • Analysis of the efficacy of ezetimibe and fenofibrate combination.
  • Assessment of safety and tolerability profiles.

Main Results:

  • Ezetimibe plus fenofibrate improves the atherogenic lipid profile in mixed hyperlipidaemia.
  • Comparative data with statin monotherapy and long-term studies are limited.
  • The combination shows promise for statin-intolerant or non-responsive patients.

Conclusions:

  • Ezetimibe plus fenofibrate is a potential second-line therapy for mixed hyperlipidaemia.
  • Further research is needed to establish its role as a first-line treatment.
  • This combination offers a valuable option for specific patient populations.

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Lipid Absorption01:24

Lipid Absorption

Dietary triglycerides from chyme in the duodenum are mixed with bile salts produced by the liver to emulsify fats. As a result, large droplets are broken down into smaller ones, increasing the surface area for enzymatic action. Once emulsified, pancreatic lipases hydrolyze the triglycerides into free fatty acids and monoglycerides.
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...
Lipid Digestion01:06

Lipid Digestion

Lipids are large molecules that are generally not water-soluble. Since most of the digestive enzymes in the human body are water-based, there are specific steps the body must take to break down lipids and make them available for use.
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...